Influence of intraoperative capsule rupture on outcomes in stage i epithelial ovarian cancer

Obstetrics and Gynecology

Volumn 113, Issue 1, 2009, Pages 11-17

  Bakkum Gamez, Jamie N ^a,c   Richardson, Debra L ^b   Seamon, Leigh G ^b   Aletti, Giovanni D ^b   Powless, Cecelia A ^b   Keeney, Gary L ^b   O'Malley, David M ^b   Cliby, William A ^b  

^a MAYO CLINIC   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; CYTOLOGY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; INTRAOPERATIVE PERIOD; KAPLAN MEIER METHOD; LOG RANK TEST; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RUPTURE; TUMOR CAPSULE RUPTURE; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PEROPERATIVE COMPLICATION; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; RUPTURE, SPONTANEOUS; SURVIVAL RATE; YOUNG ADULT;

EID: 60749112486     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181917a0c     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Ahmed FY, Wiltshaw E, A'Hern RP, Nicol B, Shepherd J, Blake P, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol 1996;14:2968-75.
3. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-9.
4. Nguyen HN, Averette HE, Hoskins W, Sevin BU, Penalver M, Steren A. National survey of ovarian carcinoma. VI. Critical assessment of current International Federation of Gynecology and Obstetrics staging system. Cancer 1993;72:3007-11.
5. Makar AP, Trope C. Fertility preservation in gynecologic cancer. Acta Obstet Gynecol Scand 2001;80:794-802.
6. Skirnisdottir I, Sorbe B. Survival and prognostic factors in earlystage epithelial ovarian carcinoma treated with taxane-based adjuvant chemotherapy. Int J Gynecol Cancer 2007;17:1231-7.
7. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007;82:751-70.
8. Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107: 77-85.
9. Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003;95:125-32.
10. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003;95:105-12.
11. Winter WE 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7.
12. Trope C, Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol 2007;25:2909-20.
13. Borgfeldt C, Iosif C, Masback A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2007;134:110-4.
14. Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003;95:113-25.
15. National Comprehensive Cancer Network. Ovarian Cancer, v. 1.2008. Available at: www.nccn.org/professionals/physician-gls/PDF/ovarian.pdf . Retrieved October 21, 2008.
16. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS, Kjorstad K. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990;75:263-73.
17. Kodama S, Tanaka K, Tokunaga A, Sudo N, Takahashi T, Matsui K. Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int J Gynaecol Obstet 1997;56: 147-53.
18. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognosis importance of intraoperative rupture. Oncology 2003;65:29-36.
19. Sainz de la Cuesta R, Goff BA, Fuller AF Jr, Nikrui N, Eichhorn JH, Rice LW. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet Gynecol 1994;84:1-7.
20. Vergote I. Prognostic factors in stage I ovarian carcinoma. Verh K Acad Geneeskd Belg 2001;63:257-71.
21. Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001;357:176-82.
22. Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni C, Bonazzi C, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborative in Ginecologia Onco-logica. Ann Oncol 1995;6:887-93.
23. Soper JT, Berchuck A, Dodge R, Clarke-Pearson DL. Adjuvant therapy with intraperitoneal chromic phosphate (32P) in women with early ovarian carcinoma after comprehensive surgical staging. Obstet Gynecol 1992;79:993-7.
24. Young RC, Brady MF, Nieberg RK, Long HJ, Mayer AR, Lentz SS, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a gynecologic oncology group study. J Clin Oncol 2003;21:4350-5.
25. Shimada M, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Minagawa Y, et al. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging. Int J Gynecol Cancer 2005;15:601-5.